Thermo Fisher Scientific has witnessed a series of significant events, with mixed implications on its stock. The company had a diminished performance in
Q2, which saw the
stock tumble, sidelining it from its Dow counterparts. This situation, however, was short-lived as strong results and a higher outlook later spurred a
stock jump. The
acquisition of Sanofi’s Ridgefield, New Jersey site, and Solventum’s Purification and Filtration business cemented Thermo Fisher's position, with some analysts foreseeing a
38% upside on the stock. Recently, the company opened a
carbon-neutral plant, reflecting its commitment to sustainability and long-term growth.
Thermo Fisher's Oncomine Dx Test gained FDA approval for NSCLC treatment. It participated in a J.P. Morgan CEO Call Series, declared a
quarterly dividend, and analysts estimated a decline in earnings. The company security
the R&D 100 awards and had a productive Q2 earnings conference call. Despite these strides, the past year has not been profitable for investors. However, a series of actions, including
strategic M&A adjustments,
cutting profit forecast on tariff hit, and exploring a
US$4 Billion Diagnostics Sale, suggest a positive outlook for Thermo Fisher.
Thermo Fisher Scientific TMO News Analytics from Thu, 20 Mar 2025 07:00:00 GMT to Fri, 05 Sep 2025 18:05:16 GMT -
Rating 2
- Innovation 8
- Information 9
- Rumor -2
